Aktieanalys

OssDsign: Analyst - ABG

ABG Sundal Collier Publicerad: 25 Jan 07:21

Q4'23 results due 6 February
Already pre-announced strong sales for Oct-Nov
Fully focused US orthobiologics company as of New Year

Q4'23 expectations

We forecast Q4 sales of SEK 33.5m, up 68% y-o-y from SEK 19.9m in Q4'22. OssDsign has already pre-announced sales for Oct-Nov (Dec 6, 2023) of SEK 25.2m, implying sales of SEK 9m in December in our Q4'23 forecast. The expected strong sales growth in Q4 is expected to have been driven by >230% sales growth for the Catalyst (orthobiologics) product to SEK 25m, from SEK 7.5m in Q4'22. We forecast Q4 adj. EBIT of -16.9m, excluding non-recurring items of SEK 15m related to the discontinuation of the CMF business during Q4'23.

Länk till analysen i sin helhet: https://cr.abgsc.com/foretag/ossdsign/Equity-research/2024/1/ossdsign---analyst/

Nyheter om OssDsign

Läses av andra just nu

Innehåller annonslänkar. Investeringar innebär risk (se här)

Tips: 50% rabatt hos fondroboten Opti

Dags att komma igång med sparande? Fondroboten Opti erbjuder en populär spartjänst som är perfekt för regelbundet månadssparande. Just nu får nya kunder som använder Börskollens unika kampanjkod BORSKOLLEN50 automatiskt 50 % rabatt på Optis avgift i 3 månader!